The use of PVP as a polymeric carrier to improve the plasma half-life of drugs

被引：171

作者：

Kaneda, Y ^{[1
]}

Tsutsumi, Y ^{[1
]}

Yoshioka, Y ^{[1
]}

Kamada, H ^{[1
]}

Yamamoto, Y ^{[1
]}

Kodaira, H ^{[1
]}

Tsunoda, S ^{[1
]}

Okamoto, T ^{[1
]}

Mukai, Y ^{[1
]}

Shibata, H ^{[1
]}

Nakagawa, S ^{[1
]}

Mayumi, T ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan

来源：

BIOMATERIALS | 2004年 / 25卷 / 16期

关键词：

polyethylene glycol (PEG); polyvinylpyrrolidone (PVP); bioconjugation; tumor necrosis factor-alpha (TNF-alpha); polymeric modifier;

D O I：

10.1016/j.biomaterials.2003.10.003

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

To achieve an optimum drug delivery such as targeting or controlled release utilizing bioconjugation with polymeric modifier, the conjugate between drugs and polymeric inodifiers must be designed to show desirable pharmacokinetic characteristics in vivo. In this study, we assessed the biopharmaceutical properties of various nonionic water-soluble polymers as polymeric drug carriers. Polyvinylpyrrolidone (PVP) showed the longest mean resident time (MRT) after i.v. injection of all nonionic polymers with the same molecular size. In fact, tumor necrosis factor-alpha (TNF-alpha) bioconjugated with PVP (PVP-TNF-alpha) circulated longer than TNF-alpha bioconjugated with polyethylene glycol (PEG-TNF-alpha) with the same molecular size. Each nonionic polymeric modifier showed a different tissue distribution. Dextran was accumulated in the spleen and liver. Polydimethylacrylamide (PDAAm) tended to distribute in the kidney. However, PVP showed the minimum volume of tissue distribution. These results suggested that PVP is the most suitable polymeric modifier for prolonging the circulation lifetime of a drug and localizing the conjugated drug in blood. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：3259 / 3266

页数：8

共 20 条

[1]

Barnard D L, 2001, Curr Opin Investig Drugs, V2, P1530

[2] PHASE-I CLINICAL-TRIAL OF RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS - A PEDIATRIC-ONCOLOGY-GROUP STUDY [J].

FURMAN, WL ;

STROTHER, D ;

MCCLAIN, K ;

BELL, B ;

LEVENTHAL, B ;

PRATT, CB .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2205-2210

[3] A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C [J].

Glue, P ;

Rouzier-Panis, R ;

Raffanel, C ;

Sabo, R ;

Gupta, SK ;

Salfi, M ;

Jacobs, S ;

Clement, RP .

HEPATOLOGY, 2000, 32 (03) :647-653

[4]

HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, P228

[5] SYNTHESIS OF A SUPEROXIDE-DISMUTASE DERIVATIVE THAT CIRCULATES BOUND TO ALBUMIN AND ACCUMULATES IN TISSUES WHOSE PH IS DECREASED [J].

INOUE, M ;

EBASHI, I ;

WATANABE, N ;

MORINO, Y .

BIOCHEMISTRY, 1989, 28 (16) :6619-6624

[6] Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting [J].

Kamada, H ;

Tsutsumi, Y ;

Sato-Kamada, K ;

Yamamoto, Y ;

Yoshioka, Y ;

Okamoto, T ;

Nakagawa, S ;

Nagata, S ;

Mayumi, T .

NATURE BIOTECHNOLOGY, 2003, 21 (04) :399-404

[7]

Kamada H, 2000, CANCER RES, V60, P6416

[8]

Kaneda Y, 1998, CANCER RES, V58, P290

[9] TARGETING CHEMOTHERAPY FOR HEPATOMA - ARTERIAL ADMINISTRATION OF ANTICANCER DRUGS DISSOLVED IN LIPIODOL [J].

KONNO, T .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :403-409

[10] Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia [J].

Kreitman, RJ ;

Wilson, WH ;

Bergeron, K ;

Raggio, M ;

Stetler-Stevenson, M ;

FitzGerald, DJ ;

Pastan, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) :241-247

← 1 2 →